A phase IIa study investigated efficacy and safety/tolerability of ascending doses of mavrilimumab ( anti-granulocyte-macrophage colony-stimulating factor receptor -LSB- GM-CSFR -RSB- monoclonal antibody ) in adult subjects with moderate to severe rheumatoid arthritis from Japan and Europe .